Latest Pharmaceutical News
Majority Of Patients' Groups Lack Trust In Pharma Firms: PatientView
Pharmaceutical companies were considered untrustworthy by majority of patients’ organisations, according to a survey conducted by a UK-based consultancy PatientView.
Published: 12-Mar-2010
Ipsen, Rhythm Sign License Agreement For Programs In Metabolic Disorders
Ipsen, a global biotechnology specialty care group and Rhythm Pharmaceuticals (Rhythm), a biotechnology company developing peptide therapeutics for metabolic diseases, have concluded a license agreement for Ipsen’s proprietary peptide therapeutics targeting obesity, metabolic diseases and gastrointestinal disorders.
Published: 12-Mar-2010
Pfizer Discontinues Phase 3 Study Of Figitumumab
Pfizer has discontinued Phase 3 trial of A4021018 (ADVIGO 1018) examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocarcinoma non-small cell lung cancer (NSCLC).
Published: 12-Mar-2010
Genentech Avastin Fails To Meet Primary End Point In Phase III Trial
Genentech, a wholly owned member of the Roche Group, has presented the results of a Phase III trial led by the US Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute (NCI).
Published: 12-Mar-2010
Abbott Seeks FDA Approval For Lupron Depot 45-mg Six Month Formulation
Abott has reported that the FDA has accepted review of the supplemental new drug application (sNDA) of a new six-month 45-mg formulation of Lupron Depot (leuprolide acetate for depot suspension) for use in the palliative treatment of advanced prostate cancer.
Published: 12-Mar-2010
Bayer HealthCare Pharma Receives ODD For Ciprofloxacin Dry Powder Inhaler
Bayer HealthCare Pharma has received orphan drug designation from FDA for ciprofloxacin dry powder inhaler (DPI) which is used in the management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis (CF) patients.
Published: 12-Mar-2010
Rexahn Pharma Gets Japanese Patent For Archexin
Rexahn Pharma has been issued a Japanese patent for its anti-cancer compound Archexin, which is currently undergoing Phase II clinical trial for the treatment of pancreatic cancer.
Published: 12-Mar-2010
Sanofi-aventis Acquires Chattem
Sanofi-aventis has completed acquisition of 100% of Chattem, which is now a wholly-owned subsidiary of the sanofi-aventis Group. With the acquisition Sanofi-aventis is building a platform for future growth and further securing its position as a global diversified healthcare company.
Published: 12-Mar-2010
Chemspec Gross Profit Down 46.7% In Q4 2009
Chemspec International, a China-based contract manufacturer of highly-engineered specialty chemicals, has reported a gross profit of RMB63m for the fourth quarter of 2009, a decrease of 46.7% from the fourth quarter of 2008. Total sales decreased 36.4% to RMB177.1m from the fourth quarter of 2008.
Published: 11-Mar-2010
Sigma-Aldrich Signs Agreement With CSIRO To Manufacture Raft Agents
Sigma-Aldrich has entered into a worldwide licensing agreement with Australia's Commonwealth Scientific and Industrial Research Organization (CSIRO) to manufacture and sell Reversible Addition-Fragmentation chain Transfer (RAFT) agents – organic molecules that can be added to polymerization reactions to precisely control molecular weights and structures of polymers.
Published: 11-Mar-2010
